ODI Pharma AB (publ) reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported sales was SEK 0.071298 million. Revenue was SEK 0.064812 million compared to SEK 0.002662 million a year ago. Net loss was SEK 2.34 million compared to SEK 0.047359 million a year ago. Basic loss per share from continuing operations was SEK 0.15.
For the nine months, sales was SEK 0.529918 million. Revenue was SEK 0.581897 million compared to SEK 0.018359 million a year ago. Net loss was SEK 4.92 million compared to SEK 2.1 million a year ago. Basic loss per share from continuing operations was SEK 0.32 compared to SEK 0.14 a year ago.